Tai康 Biotech Announces Expanded NHI Coverage for Biosimilar Drug 'Yikangping Lyophilized Injection 420mg (EIRGASUN vial 420mg)' Starting July 1
Key facts
- Tai康 Biotech Announces Expanded NHI Coverage for Biosimilar Drug 'Yikangping Lyophilized Injection 420mg (EIRGASUN vial 420mg)' Starting July 1
- Tai康 Biotech announced the expansion of national health insurance coverage for its biosimilar drug EIRGASUN 420mg for HER2-positive early breast cancer, effective July 1, 2026, enhancing patient access and expected to positively impact company operations.
- Source: TWSE
- Date: Tue Jun 16 2026 09:00:00 GMT+0900 (Japan Standard Time)
Direct answer
Tai康 Biotech announced the expansion of national health insurance coverage for its biosimilar drug EIRGASUN 420mg for HER2-positive early breast cancer, effective July 1, 2026, enhancing patient access and expected to positively impact company operations.
- Citation
- Tai康 Biotech Announces Expanded NHI Coverage for Biosimilar Drug 'Yikangping Lyophilized Injection 420mg (EIRGASUN vial 420mg)' Starting July 1 (Tue Jun 16 2026 09:00:00 GMT+0900 (Japan Standard Time)), TWSE
- Source
- TWSE
- Date
- Tue Jun 16 2026 09:00:00 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
Tai康 Biotech announced the expansion of national health insurance coverage for its biosimilar drug EIRGASUN 420mg for HER2-positive early breast cancer, effective July 1, 2026, enhancing patient access and expected to positively impact company operations.
AI Analysis
Frequently Asked Questions
- Q: What does the expanded insurance coverage mean?
- A: More HER2-positive early breast cancer patients can access affordable treatment, increasing clinical adoption.
- Q: When will the drug be available under expanded coverage?
- A: The expanded reimbursement takes effect on July 1, 2026, enabling broader prescription access.
- Q: How many patients will benefit?
- A: Approximately 1,566 to 1,755 early breast cancer patients per year are expected to benefit.